# Biohaven (BHVN) — News

BHVN · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/bhvn/news

## Recent headlines

- [Bharat Heavy 2Q EBITDA 12.86GB rupees, +69% y/y](https://www.ainvest.com/news/bharat-heavy-2q-ebitda-12-86gb-rupees-69-2610) — AInvest Wire, Oct 14, 2026
  Bharat Heavy Electricals Ltd (BHEL) reported an EBITDA of 12.86 billion rupees for the second quarter of the 2023-24 fiscal year, reflecting a year-over-year increase of 69 percent. This growth in EBITDA contrasts with the company’s consolidated net loss of Rs 238.12 crore for the same period,…
- [Biohaven to receive up to $100M in near-term payments](https://www.ainvest.com/news/biohaven-receive-100m-term-payments-2610) — AInvest Wire, Oct 8, 2026
- [Biohaven enters strategic licensing agreement with Ono Pharma for extracellular IgG degraders in Japan and select Asian regions, lead candidate BHV-1300 in phase 3 for Graves' disease](https://www.ainvest.com/news/biohaven-enters-strategic-licensing-agreement-ono-pharma-extracellular-igg-degraders-japan-select-asian-regions-lead-candidate-bhv-1300-phase-3-graves-disease-2610) — AInvest Wire, Oct 8, 2026
- [Bio-pharmaceutical stocks fell in regular trading, with Eton Pharmaceuticals down 3.3%, Livent down 5.0% and BioTelemetry down 6.2%.](https://www.ainvest.com/news/bio-pharmaceutical-stocks-fell-regular-trading-eton-pharmaceuticals-3-3-livent-5-0-biotelemetry-6-2-2609) — AInvest Wire, Sep 30, 2026
  On September 30, 2026, bio-pharmaceutical stocks experienced declines in regular trading, with several companies posting notable losses. Eton Pharmaceuticals fell 3.3%, Livent dropped 5.0%, and BioTelemetry declined by 6.2%. The sector has faced ongoing scrutiny due to stretched valuations and…
- [Biohaven shares down 9.1% premarket after US FDA places partial clinical hold on co's epilepsy drug trial](https://www.ainvest.com/news/biohaven-shares-9-1-premarket-fda-places-partial-clinical-hold-epilepsy-drug-trial-2609) — AInvest Wire, Sep 10, 2026
  Biohaven Pharmaceuticals Inc. (NASDAQ: BHVN) shares fell 9.1% in premarket trading on September 10, 2026, following news that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the company’s Phase III trial for its experimental epilepsy drug, BHV-1186. The FDA has…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).